ArticleThe Canadian journal of hospital pharmacy2013
Safety and Effectiveness of Dexmedetomidine in the Pediatric Intensive Care Unit (SAD-PICU).
Article in The Canadian journal of hospital pharmacy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients.The Cochrane database of systematic reviews · 2015Pooled it
- Dexmedetomidine Use in Critically Ill Children With Acute Respiratory Failure.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2016Trial
- Tiered Approach to Clonidine Dosing to Prevent Dexmedetomidine Withdrawal in Children: A Prospective Pre and Post Interventional Cohort Study.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database.Frontiers in pharmacology · 2024Article
- A comparison of the outcomes of dexmedetomidine and remifentanil with sufentanil-based general anesthesia in pediatric patients for the transthoracic device closure of ventricular septal defects.Journal of cardiothoracic surgery · 2021Article
- Prevention of Withdrawal in Pediatric Patients Receiving Long-term Dexmedetomidine Infusions.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Effects of a Clonidine Taper on Dexmedetomidine Use and Withdrawal in Adult Critically Ill Patients-A Pilot Study.Critical care explorations · 2020Article
- Evaluating the Transition From Dexmedetomidine to Clonidine for the Prevention of Withdrawal in Critically Ill Pediatric Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Article
- Article
- Prolonged dexmedetomidine infusion in critically ill adult patients: a retrospective analysis of a large clinical database Multiparameter Intelligent Monitoring in Intensive Care III.Annals of translational medicine · 2018Article
- Dexmedetomidine is Associated with an Increased Incidence of Bradycardia in Patients with Trisomy 21 After Surgery for Congenital Heart Disease.Pediatric cardiology · 2016Article
- Clinical recommendations for pain, sedation, withdrawal and delirium assessment in critically ill infants and children: an ESPNIC position statement for healthcare professionals.Intensive care medicine · 2016Review
- Review
- Pain and Sedation Management in Mechanically Ventilated Children.Journal of pediatric intensive care · 2015Review
- Dexmedetomidine for Sedation during Withdrawal of Support.Palliative care · 2015Article
- Survey of the Current Use of Dexmedetomidine and Management of Withdrawal Symptoms in Critically Ill Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
- Prolonged Dexmedetomidine Infusion and Drug Withdrawal In Critically Ill Children.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
- Neuroprotection and neurotoxicity in the developing brain: an update on the effects of dexmedetomidine and xenon.Neurotoxicology and teratologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCritically ill children require sedation for comfort and to facilitate mechanical ventilation and interventions. Dexmedetomidine is a newer sedative with little safety data in pediatrics, particularly for therapy lasting longer than 48 h.
objectiveTo quantify the frequency of adverse events and withdrawal syndromes associated with dexmedetomidine and to describe the use of this drug for continuous sedation in critically ill children.
methodsIn this retrospective study of patients who received dexmedetomidine for sedation in the pediatric intensive care unit, adverse events were assessed with the Naranjo scale to determine the likelihood of association with dexmedetomidine. Interventions in response to adverse events were also recorded.
resultsOne hundred and forty-four patients (median age 34 months, range 0 - 17.7 years) who underwent a total of 153 treatment courses were included. The mean infusion rate of dexmedetomidine was 0.42 μg/kg per hour (standard deviation 0.17 μg/kg per hour, range 0.05-2 μg/kg per hour). The median duration of therapy was 20.50 h (range 0.75-854.75 h), and 70 infusions (46%) lasted more than 24 h. At least one adverse event was observed in 115 (75%) of the treatment courses. Hypotension (81 [53%]) and bradycardia (38 [25%]) were the most common adverse events and were deemed "probably" attributable to dexmedetomidine in 17 (11%) and 9 (6%) of the treatment courses, respectively. In 55 of the 66 treatment courses with infusions lasting longer than 24 h for which post-infusion data were available, at least one withdrawal symptom was observed; agitation (41 [62%]) and hypertension (22 [33%]) were the most common withdrawal symptoms.
conclusionsDexmedetomidine was commonly administered for longer than 24 h in the authors' institution. Dexmedetomidine was generally well tolerated; however, the majority of patients experienced withdrawal symptoms. Patients receiving dexmedetomidine for more than 24 h should be monitored for withdrawal following discontinuation, and interventions should be provided if needed. Prospective, controlled studies are needed to characterize the safety of long-term dexmedetomidine therapy in critically ill children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.